MAP2K7 and melanoma: Furthermore, combined treatment of MEKi‐resistant A375 cells with trametinib and CQ for 7 days reduced migration/invasion into collagen compared with single‐agent treatment (Fig. S5; see Supporting Information).36 Collectively, these results indicate that autophagy modulation can contribute to resistance of BRAF‐mutant melanoma cells to MEK inhibition.